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Vascular permeability factor mRNA and protein expression in human
kidney. Vascular permeability factor (VPF), also known as vascular
endothelial growth factor (VEGF), is a potent microvascular permeabil-
ity-enhancing mediator as well as a selective mitogen for vascular
endothelium. In this study, in situ hybridization and immunohistochem-
istry co-localized VPF mRNA and protein to glomerular visceral
epithelial cells in human kidneys. Northern analysis confirmed the
presence of VPF mRNA of expected size. The finding of VPF in renal
glomerular epithelium identifies a potent mediator of permeability and
endothelial proliferation whose role in renal physiology and pathology
requires investigation.
Vascular permeability factor (VPF) is a dimeric glycoprotein
of Mr 34,000 to 42,000, consisting of two disulfide-linked
peptide chains having identical N-termini [1, 2]. As its name
implies, VPF possesses potent vascular permeability-enhancing
activity, such that, on a molar basis, it is some 50,000 times
more potent than histamine [1]. VPF was first identified in
tumor cell conditioned media [3] and has been purified to
homogeneity from guinea pig and human sources [1, 4]. VPF
acts directly on cultured vascular endothelium to induce a rapid
increase in free cytosolic calcium, apparently by activating a
phosphoinositide-specific phospholipase C [5]. It also stimu-
lates the release of von Willebrand factor from endothelial cells
[5] and induces the expression of endothelial cell tissue factor
activity [6].
Concurrent with these studies, a protein selectively mito-
genie for vascular endothelial cells was purified from cell
culture systems in several laboratories and named vascular
endothelial growth factor (VEGF) [7—i 1]. Protein and cDNA
sequencing, as well as other lines of evidence, indicate that
VPF and VEGF are products of the same gene [9, 10]. The
VPF/VEGF gene transcript may be alternatively spliced [12],
but whether alternatively spliced forms have different biologic
activities has not been determined. There is limited homology
between the VPF/VEGF gene and the gene encoding platelet-
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derived growth factor [9, 10] and more substantial homology to
another newly described protein, placenta growth factor [13].
We have recently demonstrated significant levels of VPF
mRNA in extracts of both guinea pig and human kidney by
Northern blotting [14]. In guinea pig kidneys, VPF mRNA was
localized to the glomeruli, and most likely to glomerular epithe-
hum, by in situ hybridization. Others have also localized
VPF/VEGF to glomeruli in mice [15] and rats [16]. In this study,
we have performed in situ hybridization with antisense VPF
RNA probes and immunohistochemistry with affinity purified
anti-VPF antibodies in order to determine more precisely its
cellular localization in the human kidney.
Methods
Preparation of single-stranded RNA probes for in situ
hybridization
The single-stranded RNA probe for localizing VPF mRNA by
in situ hybridization has been described previously [14]. Briefly,
we employed reverse transcription-PCR to amplify a 204-bp
VPF eDNA fragment from human fibrosarcoma cell line
HT1O8O. This 204-bp region, which is common to all known
VPF splicing variants, was subcloned into the polylinker region
of plasmid pGEM3Zf(+) (Promega, Madison, Wisconsin,
USA). The identity of the cloned insert was confirmed by DNA
sequencing. To prepare RNA probes, the pGEM construct
containing the human VPF insert was linearized with Hindlil
and transcribed in vitro from the T7 polymerase promoter to
yield the antisense probe; alternatively, the same construct was
linearized with EcoRI and transcribed from the SP6 promoter to
yield the corresponding sense (control) probe. Transcription
reactions were carried out using a Riboprobe Gemini II kit
(Promega) in the presence of (a-35S)UTP (Amersham Corp.,
Arlington Heights, Illinois, USA).
In situ hybridization
Grossly and microscopically normal-appearing portions of
five nephrectomy specimens for tumor were used in this study.
Segments of kidney that included both cortex and medulla were
fixed for four hours in 4% paraformaldehyde in phosphate
buffered saline, pH 7.6 (PBS) at 4°C and were then transferred
to a solution of 30% sucrose in PBS overnight at 4°C. Tissue
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was then frozen in OCT compound (Miles Diagnostics, Elkhart,
Indiana, USA) and stored at —70°C. Four pm frozen sections
were subjected to in situ hybridization (ISH) as previously
described [17]. Other kidney specimens were frozen fresh in
OCT compound and frozen sections were subsequently fixed
for 15 minutes in 4% paraformaldehyde solution prior to in situ
hybridization.
Inimunohistochemistry
A synthetic peptide corresponding to amino acid residues I
through 26 of human VPF was synthesized by Multiple Peptide
Systems, San Diego, California, USA. The peptide sequence, in
single letter code was: APMAEGGGQNHHEVVKFMDVYQR-
SYC with an amide replacing a carboxyl group at the C-termi-
nus. The peptide was coupled to keyhole limpet hemocyanin
and rabbits were immunized as previously described for a
similar peptide based on guinea pig sequence [1]. Anti-peptide
antibody was affinity purified on columns prepared by conjuga-
tion of 5 mg peptide to 1 g of CnBr-activated Sepharose
(Pharmacia). Typically, 20 ml of antiserum was passed over the
column after which the column was washed with phosphate
buffered saline. Bound antibody was eluted with 15 ml of 0.1 M
acid glycine buffer, pH 2.5. Eluted antibody was immediately
diluted in 2 ml of 1 M Tris buffer, pH 8.0, and dialyzed against
phosphate buffered saline. Affinity-purified antibody concentra-
tions were typically 0.5 mg/ml. The anti-peptide antibody bound
VPF in ELISA assays and on immunoblots.
Immunohistochemistry was performed on 4 m unfixed fro-
zen sections or frozen sections of tissue fixed in paraformalde-
hyde using the affinity purified anti-VPF antibody with an
avidin-biotin peroxidase conjugate protocol (Vector Lab, Bur-
lingame, California, USA). Normal rabbit IgG diluted to an
equivalent concentration was substituted for the primary anti-
body as a control.
Northern hybridization
For Northern analysis, the human VPF cDNA insert from the
pGEM construct described above was labeled with (a-32P)
dCTP (New England Nuclear, Boston, Massachusetts, USA) to
a specific activity of ——2 x l0 cpm/tg DNA using the random
hexamer labeling method [18]. Total RNA was prepared from
human kidney and from cultured HT1O8O cells using a guanidi-
nium isothiocyanate lysis-CsCl gradient method [19]. RNA
samples (20 g per lane) were size-fractionated on 1.2% agarose
containing 6% formaldehyde and blotted on Nytran membranes
(Schleicher and Schuell, Keene, New Hampshire, USA). Hy-
bridization was performed as previously described 114]. Final
washes were carried out at high stringency (0.1 x SSC, 0.1%
SDS at 65°C). Blots were exposed to Kodak XAR-2 film with an
intensifying screen at —70°C for two days. To control for total
mRNA content and lack of degradation, the blots were stripped
and subsequently hybridized with human /3-actin probe.
Results
Northern blots of RNA preparations from three different
human kidneys, including both cortex and medulla, were
probed with VPF cDNA, demonstrating significant levels of
VPF mRNA of expected size, -—-4.5 kb (Fig, 1). The cDNA
probe used in these experiments was designed to recognize all
3-actin
known VPF variants. RNA from human fibrosarcoma cell line
HT1O8O, known to be a rich source of VPF, served as a positive
control.
In situ hybridization was performed on five human kidneys in
order to localize VPF mRNA at the cellular level (Fig. 2). In all
cases, antisense probe strongly labeled a population of glomerular
cells. When these were situated peripherally in the glomerular
tuft, they could be confidently identified as visceral epithelial
cells. More centrally situated cells, morphologically identical to
labeled peripheral cells, were also labeled and these were
probably also epithelial cells. Glomerular endothelial cells were
not significantly labeled with the VPF probe, but rare tubular
epithelial cells were labeled lightly. No specific cellular labeling
was seen with sense control probes, and nonspecific back-
ground was low.
Immunohistochemical staining with affinity purified antibod-
ies to the human VPF N-terminus demonstrated definitively
that glomerular visceral epithelial cells contained VPF (Fig. 3).
Staining was cytoplasmic and highlighted the epithelial cells'
extensive elongate processes which surrounded glomerular
capillary endothelial cells. All visceral glomerular epithelial
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Fig. 1. Northern blot of RNA isolated from a normal adult human
kidney and from human fibrosarcoma HTIO8O cells probed with 32P-
labeled VPF cDNA (top panel) and 13-actin cDNA (bottom panel). The
positions of 28S and 18S rRNA species on the original gel are marked.
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Fig. 2. In situ hybridization of glomeruli from normal adult human kidneys. A,B. VPF antisense riboprobe labeling of a glomerulus as visualized
by brightfield (A) and darkfield (B) microscopy (x300). Note intense labeling of individual cells at the periphery of the glomerulus and within the
glomerulus. Immediately surrounding tubular epithelium shows little consistent labeling. C,D. VPF sense riboprobe application to an adjacent
section of kidney visualized by brightfield (C) or darkfield (D) microscopy (x300). Note low background and lack of specific cellular labeling.
cells stained with apparently equal intensity. In contrast, endo-
thelial cells, parietal glomerular epithelial cells and tubular
epithelium did not stain. No specific cellular staining was seen
with control rabbit IgG.
Discussion
The data presented here indicate that both VPF mRNA and
VPF protein are present in readily detected amounts in normal
adult human kidneys. Northern analysis performed on whole
kidney RNA revealed a VPF mRNA transcript of expected size
(—4,5 kb). In situ hybridization and immunohistochemistry
localized both VPF mRNA and VPF protein to glomerular
visceral epithelium. Rare tubular epithelial cells also hybridized
weakly with antisense riboprobes to VPF mRNA, but the
labeling was far less than that seen in glomeruli. No convincing
tubular staining for VPF was seen by immunohistochemistry.
These data indicate that renal glomerular epithelial cells
express VPF mRNA. Notably, the pattern of immunohisto-
chemical staining for VPF in kidneys differs somewhat from
that described in tumors [20]. Tumor cells stained relatively
weakly with antipeptide antibodies to VPF, possibly because
VPF was constitutively secreted and not stored; however,
endothelial cells adjacent to tumors which did not express VPF
mRNA nonetheless stained intensely for VPF, suggesting that
tumor-secreted VPF accumulated on nearby target endothe-
hum. In contrast to tumors, no such VPF accumulation was
observed in normal renal glomerular capillaries, however, the
possibility that a small amount of VPF was present on these
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Fig. 3. Immunohistochemistry of normal human kidney with an antipeptide antibody to the N-terminus of human VPF. Note intense staining of
glomerular visceral epithelial cells and their elongate cytoplasmic processes in A (x400) and, at higher power (x600) in B.
capillaries could not be excluded given the intense glomerular
epithelial staining and the limited resolution of light micros-
copy.
The roles that VPF plays in normal renal physiology and in
renal disease have not been investigated, but it is likely that, as
in other organs and tissues, VPF acts on endothelial cells and
mediates functions such as vascular permeability and endothe-
hal cell division. This view is reinforced by the intimate
anatomic relationships that exist between the glomerular vis-
ceral epithelial cells that synthesize VPF and the glomerular
vascular endothelium; secreted VPF needs only cross the
intervening glomerular basement membrane to reach glomeru-
lar endothehjal cells. Labeled VPF has been shown to bind to
endothelial cells in the renal cortex (most intensely in the
glomeruli) and medulla [21], suggesting that endothelial cells in
the kidney express receptors for VPF.
VPF is a potent microvascular permeability-enhancing agent
in skin, peritoneal wall, subcutaneous tissue, skeletal muscle
and likely in other organs that have not as yet been tested;
therefore, it is tempting to speculate that VPF may have a role
in regulating normal renal glomerular permeability. Filtration of
plasma is the major function of the glomerulus and is critical to
renal function. Most investigators feel that the glomerular
basement membrane and endothelium are primarily responsible
for the selective permeability exhibited by the glomerulus,
regulating molecular passage on the basis of size and charge
[22]. The role of the glomerular epithelial cell in permeability
regulation has been less clear. The visceral epithelial cell
contributes to the synthesis and maintenance of the glomerular
basement membrane. The epithelial slit pore, a specialized
membrane between the foot processes, is so situated that it too
could have a role in limiting molecular filtration. Injury to
visceral epithelium is a crucial component in the development
of proteinuria and glomerulosclerosis in experimental chronic
hyperfiltration models [23, 24]. It is interesting to speculate that
glomerular epithelial injury leads to increased VPF synthesis
and/or secretion and thereby to abnormal glomerular permeabil-
ity. VPF may thus be found to be an important mediator of renal
glomerular dysfunction, and VPF itself, or inhibitors of its
activities, may provide novel treatments for at least some
glomerular disorders.
VPF/VEGF is also known as a selective endothelial cell
mitogen. VPF/VEGF could have a role in maintaining glomer-
ular endothelial cell number and function. In certain patholog-
ical states, VPF/VEGF might serve to stimulate glomerular
endothelial cell division.
In addition to VPF, normal kidneys express a number of
other growth factors. Transforming growth factor /31 and /32
mRNA have been detected in normal rat glomeruli but cellular
localization was not defined [25]. In addition, epidermal growth
factor mRNA has been localized to the thick ascending limb of
Henle and the early distal convoluted tubular epithelium by in
situ hybridization in the mouse [261. Insulin-like growth factor-i
synthesis has been localized to collecting ducts by immunohis-
tochemistry and RNA analysis of isolated segments of the rat
nephron [27]. Basic fibroblast growth factor mRNA has been
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identified in cultured rat glomerular epithelial cells by reverse
transcriptase PCR [281. The actions and possible interactions of
these growth factors with VPF need to be explored in order to
gain a better understanding of the regulation of renal function.
In summary, data presented here establish the presence of
VPF/VEGF in the visceral glomerular epithelium of human
kidneys. The precise roles of VPF in normal renal physiology
and in renal disease remain to be determined, but given what is
known about the biology of VPF/VEGF, VPF could play
important roles in both the regulation of glomerular permeabil-
ity and in glomerular endothelial cell growth.
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